CapsoVision, Inc. filings document a commercial-stage medical technology company focused on AI-enabled capsule endoscopy and gastrointestinal imaging. The company’s SEC record includes registration statements for common stock offerings and resale registration matters, 8-K reports on financial results, private placement financing, material development agreements and FDA-related product updates.
CapsoVision’s proxy materials cover annual meeting voting, board matters and public-company governance. Other disclosures address the company’s capital structure, common stock issuances, executive officer appointments, equity incentive arrangements, indemnification agreements, operating results and development spending tied to CapsoCam Plus®, CapsoCam Colon™ and related imaging technology.
CapsoVision, Inc insider Shen Ching Hang filed an initial Form 3 reporting significant ownership of the company’s common stock. The filing shows 4,352,606 shares held directly and 2,047,921 shares held indirectly through Star One Global Capital Limited, indicating a large, more than ten percent stake, with no new buy or sell transactions reported.
CapsoVision, Inc insider Harari Eliyahou et al, reported as a more than ten percent owner, filed an initial statement of beneficial ownership of common stock. As of March 16, 2026, the reporting person held 878,448 common shares directly.
In addition, indirect holdings held "by trust" included 3,186,901 common shares in one trust and 517,759 common shares in each of two other trusts, for which the reporting person and spouse serve as trustees. The filing shows ownership positions only and does not report any new purchases or sales.
CapsoVision, Inc. is a commercial-stage medical technology company focused on capsule endoscopy for gastrointestinal (GI) diagnosis. Its core product, CapsoCam Plus for small-bowel imaging, generated about $13.6 million in revenue for the year ended December 31, 2025, up from $11.8 million in 2024, driven mainly by higher capsule volumes and growing U.S. and international adoption.
The company is adding AI-assisted pathology detection to CapsoCam Plus and developing accessories such as a delivery device and patency capsule. A major growth driver is expected to be CapsoCam Colon, a colon capsule with 360° imaging, AI polyp detection, and 3D size measurement, but it is not yet cleared. CapsoVision discontinued its first-generation colon 510(k) submission after FDA feedback and is now prioritizing a second-generation version, targeting a new 510(k) filing in the third quarter of 2026.
CapsoVision operates in a competitive, regulated market and faces significant risks. It has a history of net losses, and its audited 2024 and 2025 financial statements include a going concern footnote, reflecting substantial doubt about its ability to continue without additional financing. Future growth depends on successful regulatory clearances, reimbursement support, expansion beyond small-bowel indications, and managing supply-chain and geopolitical risks tied to key single-source suppliers in Asia.
CapsoVision reported fourth quarter and full-year 2025 results showing solid revenue growth but continued significant losses. Fourth quarter 2025 revenue was $3.9 million, up 13% year over year, and full-year 2025 revenue was $13.6 million, a 15% increase driven mainly by higher CapsoCam Plus capsule sales.
Full-year gross profit was $7.2 million with a 53% gross margin, slightly below 54% in 2024, while operating expenses rose to $32.7 million due to R&D, clinical activities, and public company costs. Net loss widened to $25.3 million, or $1.03 per share.
Cash and cash equivalents totaled $10.1 million as of December 31, 2025. The company completed an initial public offering with $23.4 million in net proceeds and subsequently closed a $14 million private placement in March 2026. Operationally, CapsoVision submitted a 510(k) application for its AI-assisted module for CapsoCam Plus and continued developing its colon and upper GI capsule pipeline.
Tsai Chen Lung reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. director Tsai Chen Lung reported receiving a grant of 4,045 Restricted Stock Units on March 19, 2026. Each RSU represents a contingent right to receive one share of CapsoVision common stock, giving him rights to 4,045 underlying shares after this award.
The RSUs vest in two equal installments, with 50% scheduled to vest on June 30, 2026 and the remaining 50% on December 31, 2026, subject to his continued service on the board through each vesting date. Following this grant, he holds 4,045 RSUs directly.
Kuo Hui Ying reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. reported that director Kuo Hui Ying received a grant of 4,045 Restricted Stock Units (RSUs), each representing one share of common stock. This is a compensation-related award rather than an open-market trade, and it brings the director’s reported holdings to 4,045 RSUs.
The RSUs vest in two equal parts: 50% on June 30, 2026 and 50% on December 31, 2026, conditioned on continued service on the board through each vesting date. No cash price was paid for the award.
King Wen-Herng Henry reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc director King Wen-Herng Henry reported receiving a grant of 4,045 Restricted Stock Units (RSUs) tied to the company’s common stock. Each RSU represents a contingent right to receive one share of common stock if vesting conditions are met.
The award is scheduled to vest in two equal tranches, with 50% vesting on June 30, 2026 and the remaining 50% vesting on December 31, 2026, subject to his continued service on the board through each vesting date. Following this grant, his reported direct holdings consist of 4,045 RSUs.
Imperial Joanne Carol reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc director Joanne Carol Imperial received a grant of 4,045 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of CapsoVision common stock.
The award vests in two equal installments: 50% on June 30, 2026 and 50% on December 31, 2026, subject to her continued service as a non-employee director through each vesting date. Following this grant, she holds 4,045 RSUs directly, and this filing reflects a compensation-related award rather than an open-market share purchase or sale.
Harari Michele reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. reported that director Michele Harari received a grant of 4,045 restricted stock units (RSUs), each representing the right to receive one share of common stock. The award is a form of equity compensation rather than an open-market purchase.
The RSUs are scheduled to vest in two equal installments, with 50% vesting on June 30, 2026 and the remaining 50% on December 31, 2026, subject to Harari’s continued service on the board through each vesting date. Following this grant, Harari holds 4,045 RSUs directly.
GOUW JULIA S reported acquisition or exercise transactions in this Form 4 filing.
CapsoVision, Inc. reported that director Julia S. Gouw received a grant of 4,045 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of CapsoVision common stock, so the grant covers 4,045 potential shares.
The RSUs vest in two equal tranches, with 50% scheduled to vest on June 30, 2026 and the remaining 50% on December 31, 2026. Vesting is conditioned on her continued service as a non-employee director on the board through each vesting date.